Board of Directors

Richard A. Meier joined our Board in December 2006 and has served as our Chair of the Board since December 2023. Since November 2019, Mr. Meier has served as Executive Vice President and Chief Financial Officer of Intersect ENT, Inc., a public medical technology company. Mr. Meier served as President-International and Executive Vice President and Chief Financial Officer of Owens & Minor, Inc., a global healthcare services company, from July 2015 to July 2018, and was Executive Vice President and Chief Financial Officer of Owens & Minor, Inc. from March 2013 to July 2015. Prior to joining Owens & Minor, Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company from January 2010 through March 2012. Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009, from November 2007 to May 2009. Beginning in April 2002 through November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles including Chief Operating Officer. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Bausch Health Companies, Inc. (BHC) (formerly Valeant Pharmaceuticals, Inc. and ICN Pharmaceuticals, Inc.), from October 1999 to April 2002, and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining BHC, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier is a member of the Supervisory Board of Syntellix AG, a private medical technology company, and he was a Director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016, where he also served on the Governance, Compensation and Audit Committees. Mr. Meier holds a B.A. in economics from Princeton University.

Mr. Alles served as Chief Executive Officer of Celgene Corporation, a global biopharmaceutical company, from March 2016 and as Chairman and Chief Executive Officer from February 2018 until its acquisition by Bristol Myers Squibb Company in November 2019. Prior to these roles, he served as Celgene’s President and Chief Operating Officer from August 2014 to February 2016 and as its Chief Commercial Officer and Executive Vice President, Hematology & Oncology from December 2012 to July 2014. Mr. Alles first joined Celgene in 2004 and served in a number of commercial management positions of increasing responsibility at the company. Before joining Celgene, he held senior commercial management roles at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) from 1993 to 2004. He is currently Chairman of Turning Point Therapeutics, Inc., a public oncology company, and also serves on the boards of Antengene Corporation Limited and Syros Pharmaceuticals, Inc., both public biopharmaceutical companies. Mr. Alles received a bachelor’s degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps.

Elizabeth McKee Anderson joined our Board in July 2019 and serves as Chair of the Compensation Committee. Ms. Anderson held various senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. Ms. Anderson most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. Prior to Johnson & Johnson, Ms. Anderson served as the Vice President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002. Ms. Anderson also previously worked at Rhône-Poulenc Rorer and the American Red Cross. Ms. Anderson currently serves on the boards of GSK PLC, Insmed, Inc. and Revolution Medicines, Inc., all public biopharmaceutical companies, and she formerly served on the boards of Bavarian Nordic A/S, a public vaccines and biopharmaceuticals company, through August, 2022 and Huntsworth PLC, a public healthcare and communications company, through December 31, 2019. Ms. Anderson also serves on the board of Aro Biotherapeutics Company, a private biopharmaceutical company, is an advisory board member of Naxion Inc., a private research and consulting company, is a member of the Board of Trustees of the Wistar Institute, a non-profit biomedical research organization and is the Principal of PureSight Advisory, LLC. Ms. Anderson holds a B.S. in Engineering from Rutgers University and an M.B.A. from Loyola University Maryland.

Mr. Bienaimé retired in December 2023 as Chairman and Chief Executive Officer of 澳门正规博彩十大排行平台, and currently serves as a member of the company’s Board of Directors. During his 18 years as CEO, Mr. Bienaimé helped lead the company through a period of significant growth, overseeing the approval of seven new medicines, including the company’s globally leading enzyme replacement therapies and the recent introductions of VOXZOGO^® for achondroplasia and ROCTAVIAN™, the world’s first gene therapy for hemophilia A. During his tenure, Mr. Bienaimé led the growth of the business from annual revenues of approximately $26 million when he started to more than $2 billion. He also oversaw a major expansion of 澳门正规博彩十大排行平台’s workforce, from about 300 employees only in the United States when he joined the company to more than 3,000 people in almost 80 countries around the world at the time of his retirement.

Prior to 澳门正规博彩十大排行平台, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership from 2002 to 2005, Genencor’s revenues and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of more than $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corp. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals, where he was responsible the U.S. launch of Lovenox for the prevention of pulmonary embolism and treatment of unstable angina and global launch of Taxotere for breast and lung cancers. Earlier in his career, he worked at Genentech, Inc., where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.

Mr. Bienaimé currently serves on the boards of Incyte Corp., the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO). He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

Barbara Bodem, who has served on the 澳门正规博彩十大排行平台 Board since December 2023, was interim Chief Financial Officer for Dentsply Sirona from April to October 2022. Prior to that, she served as Senior Vice President and Chief Financial Officer, at Hillrom. Earlier in her career, she served as Senior Vice President of Finance for Mallinckrodt Pharmaceuticals. She previously served in senior finance roles at Hospira and Eli Lilly.

Ms. Bodem also serves on the boards of Enovis Corp., BiomEdit and Option Care Health, as well as the nonprofit Nature Conservancy of Indiana. Previously, Ms. Bodem served on the boards of Syneos Health, Turning Point Therapeutics and Invacare.

She holds an M.B.A and a B.S. in Finance, both from Indiana University.

Athena Countouriotis, M.D., who has served on the 澳门正规博彩十大排行平台 Board since December 2023, is co-founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics. Prior to that, she served as President and Chief Executive Officer of Turning Point Therapeutics, leading the company through its initial public offering and eventual acquisition by Bristol Myers Squibb. Before that, Dr. Countouriotis held the role of chief medical officer at Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol Myers Squibb.

Dr. Countouriotis also serves on the boards of Iovance Biotherapeutics and Passage Bio.

She earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine.

Willard Dere, M.D. joined our Board in July 2016 and serves as Chair of the Science and Technology Committee. He is currently Professor Emeritus of Internal Medicine at the University of Utah and Chief Advisor to the CEO at Angitia Biopharmaceuticals, a private biopharmaceutical company. From November 2014 to June 2022, Dr. Dere served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Co-Director of the Utah Clinical and Translational Science Institute, Co-Director of the Center for Genomic Medicine, and the Associate Vice President for Research at the University of Utah Health Sciences Center. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as senior vice president of global development, and either the international or corporate chief medical officer from December 2004 to October 2014. Dr. Dere began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. Dr. Dere currently serves on the boards of Mersana Therapeutics, Inc. and Seres Therapeutics, Inc., both public biopharmaceutical companies, and Metagenomi, a privately-held biopharmaceutical company. In December 2017 Dr. Dere concluded his board service at Ocera Therapeutics, Inc., a public biopharmaceutical company, before its acquisition by Mallinckrodt PLC, and in 2022, he concluded his board service at Radius Health, which was acquired by a private equity firm. Dr. Dere also serves on the external advisory boards of the Utah Clinical and Translational Science Institute, and the Clinical and Translational Science Center at the University of California Davis School of Medicine. Since 2014, Dr. Dere has served on the Grants Working Group of the California Institute of Regenerative Medicine. Dr. Dere received a B.A. and an M.D. from the University of California, Davis, and trained in internal medicine at the University of Utah and in endocrinology/metabolism at the University of California at San Francisco.

Mark Enyedy, who joined the 澳门正规博彩十大排行平台 Board in December 2023, is President and Chief Executive Officer of ImmunoGen. Mr. Enyedy has nearly three decades of combined general management, business development and legal experience in the biotechnology industry. Mr. Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development. Prior to that, Mr. Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corp. Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.

Mr. Enyedy also serves on the boards of The American Cancer Society of Eastern New England and the Biotechnology Innovation Organization. He previously served on the boards of Ergomed plc, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals.

He holds a J.D. from Harvard Law School and a B.S. from Northeastern University.

Alexander Hardy serves as President and Chief Executive Officer of 澳门正规博彩十大排行平台 and a member of the company’s Board of Directors.

Alexander joined 澳门正规博彩十大排行平台 in December 2023 after more than 30 years in the global biopharmaceutical industry. Prior to 澳门正规博彩十大排行平台, he spent nearly 20 years at Genentech and Roche, most recently serving as chief executive officer of Genentech. During his time as Genentech’s CEO, he oversaw the successful launch of 10 innovative medicines and spearheaded the company’s entrance into several new therapeutic areas. Prior to that, Alexander led Roche’s Global Product Strategy organization and before that served as head of Asia Pacific for Roche. Earlier in his career, Alexander held a number of international leadership roles at Novartis. Alexander serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).

Throughout his career, Alexander has championed a vibrant company culture that inspires employees to improve human health. He is an advocate for diversity, equity and inclusion to promote belonging within organizations and advance inclusive research across the biopharmaceutical industry.

Alexander completed his undergraduate education at University of Cambridge in the UK and earned his M.B.A. at the University of Michigan’s Ross School of Business. He lives in the San Francisco Bay Area with his wife and three daughters.

Elaine J. Heron, Ph.D. joined our Board in July 2002. From February 2009 to October 2015, Dr. Heron served as Chair and CEO of Amplyx Pharmaceuticals, Inc., a private drug development company acquired by Pfizer, Inc. in April 2021. Dr. Heron currently serves on the boards of Vaxart, Inc., a public clinical-stage biotechnology company, Visgenx, Inc., a private preclinical-stage therapeutics company, and Watershed Medical, Inc., a private early-stage therapeutics company. Dr. Heron is also an advisor to Kyto Technology and Life Science, Inc. and Cairn Biosciences, Inc. From July 2001 to October 2008, Dr. Heron was Chair and CEO of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., Dr. Heron spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Dr. Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.

Maykin Ho, Ph.D. joined our board in February 2021. Dr. Ho serves on the boards of Agios Pharmaceuticals, a public pharmaceutical company, FibroGen, Inc., a public biopharmaceutical company, Neumora Therapeutics, Inc., a private biotechnology company, and Parexel, a private biopharmaceutical services company, the Aaron Diamond AIDS Research Center at Columbia University, and the Institute for Protein Innovation founded by Dr. Timothy Springer of Harvard University. Dr. Ho is also a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. Dr. Ho was previously a member of the board of directors of Grail, Inc., a private cancer detection company that was acquired by Illumina. Dr. Ho is also a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of global healthcare investment research, and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. Dr. Ho was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center.

Robert J. Hombach joined our Board in September 2017 and currently serves as Chair of the Audit Committee. Mr. Hombach served as Executive Vice President, CFO, and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc., a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. Mr. Hombach served as Corporate Vice President and CFO of Baxter from July 2010 until the spin-off in June 2015. Mr. Hombach also served as Treasurer of Baxter from 2007 to 2011 and was Vice President of Finance, Europe, Middle East and Africa from 2004 to 2007. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the boards of Aptinyx Inc., a public biopharmaceutical company, and Embecta Corporation, a public diabetes company. Previously, Mr. Hombach served on the board of CarMax, Inc., a public company, from April 2018 to June 2022, and the board of Naurex, Inc., a private pharmaceutical company acquired by Allergan in 2015. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management, and a B.S. in Finance cum laude from the University of Colorado.

Bryan Lawlis, Ph.D. joined our Board in June 2007. Dr. Lawlis served as the President and CEO of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc., a private biotechnology company, from August 2011 to September 2017. Dr. Lawlis co-founded and served as President and CEO of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and CEO of Aradigm Corporation, a public pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and CEO from 1996 to 1999, and as its Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. from 1981 to 1996. Dr. Lawlis’ last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis serves on the boards of Aeglea BioTherapeutics, Inc. and Geron Corporation, both public biopharmaceutical companies. Dr. Lawlis previously served on the board of Coherus BioSciences from January 2004 until June 2019. Dr. Lawlis currently holds a board position at 1Cbio, Inc., a private company and serves as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. Dr. Lawlis also serves on the Manufacturing Advisory Boards of Allakos, Inc. and Pyxis Oncology and on the Scientific Advisory Boards of Comera Life Sciences (formerly ReForm Biologics), Absci Corp. and Coherus BioSciences in addition to advising W.L. Gore and Associates. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.

David E.I. Pyott, M.D. (Hon.), joined our Board in January 2016. From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. Dr. Pyott serves on the boards of Alnylam Pharmaceuticals, Inc., a public biotechnology company and Pliant Therapeutics, Inc., a public biopharmaceutical company, and he is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health and technology company. Dr. Pyott serves as Chairman of Bioniz Therapeutics, Inc., a private biotechnology company. He is Deputy Chairman of the Governing Board of the London Business School, is a member of the Board of Trustees of the California Institute of Technology and President of the Ophthalmology Foundation. Dr. Pyott formerly served as Lead Director at Avery Dennison Corporation, a public global labeling and packaging materials company, through April 23, 2020. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.

Dennis J. Slamon, M.D., Ph.D., joined our Board in March 2014. Dr. Slamon has served as director of Clinical/ Translational Research at UCLA’s Jonsson Comprehensive Cancer Center since June 1995 and has served as leader of the Revlon/UCLA Women’s Cancer Research Program at UCLA since its establishment in 1991. Since May 1996, Dr. Slamon has been a professor of medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and executive vice chair for research for UCLA’s Department of Medicine. He also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a research and fund-raising organization that promotes advances in the treatment of colorectal cancer, and he is member of the board of Translational Research in Oncology, a global, non-profit, academic clinical research organization. Dr. Slamon was awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the development of a breast cancer drug. A 1970 B.A. honors graduate in biology from Washington & Jefferson College and a 1975 graduate of the University of Chicago Pritzker School of Medicine, Dr. Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the faculty of medicine.